Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole in Adults with Borderline Personality Disorder
NCT04100096Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of brexpiprazole orally disintegrating tablet in borderline personality disorder (BPD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2019; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT04100096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100096.